EPCAM and non-small cell lung carcinoma: In our cohort of patients with head and neck and NSCLC, we found that the Parsortix approach identified a higher proportion of CTC-positive patients than the CellSearch® system, indicating that an antigen CTCs independent isolation approach can overcome the EpCAM expression heterogeneity that characterizes these tumors.